Biomerica, Inc. (NASDAQ:BMRA) Expected to Post Quarterly Sales of $1.36 Million

Brokerages forecast that Biomerica, Inc. (NASDAQ:BMRA) will announce $1.36 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Biomerica’s earnings. The highest sales estimate is $1.52 million and the lowest is $1.20 million. Biomerica reported sales of $1.13 million during the same quarter last year, which indicates a positive year-over-year growth rate of 20.4%. The business is scheduled to issue its next earnings report on Thursday, August 29th.

On average, analysts expect that Biomerica will report full-year sales of $5.40 million for the current fiscal year, with estimates ranging from $5.24 million to $5.55 million. For the next financial year, analysts expect that the company will report sales of $6.20 million, with estimates ranging from $6.08 million to $6.31 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Biomerica.

Separately, B. Riley set a $6.00 target price on shares of Biomerica and gave the stock a “buy” rating in a research note on Friday, July 19th.

A hedge fund recently bought a new stake in Biomerica stock. Heritage Investors Management Corp acquired a new stake in shares of Biomerica, Inc. (NASDAQ:BMRA) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,550 shares of the company’s stock, valued at approximately $39,000. Heritage Investors Management Corp owned 0.17% of Biomerica at the end of the most recent quarter. 1.31% of the stock is currently owned by institutional investors and hedge funds.

Shares of Biomerica stock traded down $0.15 on Friday, reaching $3.32. The stock had a trading volume of 2,629 shares, compared to its average volume of 51,156. The firm’s 50 day moving average price is $2.76. Biomerica has a 1 year low of $1.60 and a 1 year high of $3.94. The stock has a market cap of $33.55 million, a PE ratio of -19.53 and a beta of 1.33.

About Biomerica

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Biomerica (BMRA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.